Dentsply Sirona generated Q4 2025 net sales growth of 6.2% to 961000000, but recorded a GAAP net loss of 146000000 due to goodwill and intangible impairments, while adjusted EBITDA increased to 135000000.

Dentsply Sirona reported a GAAP net loss of $427 million in Q3 2025 due to $263 million in impairment charges. Revenue declined 5% year-over-year to $904 million, but adjusted EPS was positive at $0.37. The company also introduced a Return-to-Growth strategy to improve performance.

Dentsply Sirona reported a decrease in net sales by 4.9% to $936 million in Q2 2025 compared to the prior year. Despite the top-line decline, the company achieved adjusted EPS of $0.52, up from $0.49, and expanded its adjusted gross margin to 55.9% and adjusted EBITDA margin to 21.1%. The company also recorded a significant non-cash impairment charge of $214 million net of tax.

Dentsply Sirona reported a decrease in net sales for Q1 2025, driven by a decline in the United States and Orthodontic and Implant Solutions segment. Despite the sales challenges, the company saw improvements in adjusted EBITDA margin and maintained its full-year adjusted EPS outlook.

Dentsply Sirona reported a decrease in net sales by 4.2% to $984 million, with a net loss of $4 million, or ($0.02) per share. Adjusted EPS was $0.49. The company is revising its full-year outlook to reflect lower expected sales and adjusted EPS. A second phase of transformation is expected to reduce annualized operating expenses by $80 to $100 million over approximately 12 to 18 months.

Dentsply Sirona reported a decrease in net sales and organic sales for Q1 2024. While GAAP EPS was $0.09, adjusted EPS reached $0.42. The company is maintaining its FY24 outlook but expects to trend towards the lower end of the range.

Dentsply Sirona's Q4 2023 results showed a 2.9% increase in net sales, reaching $1,012 million, and a net income of $67 million, or $0.32 per share. Adjusted EPS was $0.44, slightly down from $0.46 in the same quarter of the previous year. The company's full year 2024 outlook includes organic sales flat to up 1.5% and adjusted EPS of $2.00 to $2.10.

Dentsply Sirona reported flat net sales of $947 million year-over-year in Q3 2023. The company experienced a GAAP net loss of $266 million, or $1.25 per share, but adjusted EPS increased to $0.49. The company is revising its full-year outlook to organic sales growth of approximately 1% and adjusted EPS of $1.80 to $1.85.

Dentsply Sirona reported a slight increase in net sales, driven by organic growth across all segments. The company raised its full-year outlook for net sales, organic sales growth, and adjusted EPS.

Dentsply Sirona reported a 0.9% increase in net sales to $978 million for Q1 2023, with organic sales up 5.1%. However, the company experienced a GAAP net loss of $19 million, or ($0.09) per share. Despite the loss, Dentsply Sirona is raising the low-end of its full-year outlook for net sales and adjusted EPS.

Dentsply Sirona's Q4 2022 net sales decreased by 10.9% to $983 million, and GAAP EPS was ($0.07). Adjusted EPS decreased to $0.46, compared to $0.83 in Q4 2021. The company's results exceeded the high end of its prior sales and EPS outlook ranges.

Dentsply Sirona's Q3 2022 results showed a net sales decrease of 8.9% to $947 million, with organic sales down 0.7%. The company reported a GAAP EPS loss of ($5.01) and an adjusted EPS of $0.41, a 31.5% decrease year-over-year. Operating cash flow was $109 million.

Dentsply Sirona restated its Q2 2022 results due to an internal investigation and errors in revenue recognition. Net sales were $1.023 billion, and net income attributable to Dentsply Sirona was $73 million, or $0.34 per diluted share. Adjusted non-GAAP net income was $149 million, or $0.69 per diluted share.

Dentsply Sirona's Q1 2022 net sales decreased by 6.1% to $965 million, with a 1.4% decrease in organic sales. EPS was $0.30, and adjusted EPS decreased to $0.52 compared to $0.72 in Q1 2021. The company updated its FY22 outlook, projecting organic sales growth of 2% to 3% and an adjusted EPS range of $2.35 to $2.55.

Dentsply Sirona's Q4 2021 results showed a slight increase in net sales but a decrease in adjusted earnings per share. Net sales increased by 0.6% to $1,088 million, while adjusted EPS decreased to $0.76 compared to $0.87 in the fourth quarter of 2020.

Dentsply Sirona reported a strong third quarter with a 19.4% increase in revenue to $1,069 million and GAAP EPS increasing to $0.47. Organic revenue grew by 21.1%, driven by recovery in the dental market and product launches. The company also raised its full-year 2021 Non-GAAP EPS outlook to $2.87 to $2.92.

Dentsply Sirona reported a substantial increase in revenue and earnings for Q2 2021. Revenue increased by 117.3% to $1,067 million, and GAAP EPS increased to $0.45 compared to a loss of ($0.44) in 2020. The company reaffirmed its FY21 Non-GAAP EPS outlook of $2.75 to $2.90.

Dentsply Sirona reported a strong first quarter in 2021, with a 17.5% increase in revenue to $1,027 million and a significant rise in both GAAP and non-GAAP EPS. The company has raised its full-year 2021 non-GAAP EPS outlook.

Dentsply Sirona's Q4 2020 net sales reached $1.08 billion, a decrease of 2.6% compared to Q4 2019. GAAP EPS decreased by 2.2% to $0.45, while Non-GAAP EPS increased by 19.2% to $0.87. The company's operating income decreased by 1.5% to $135 million, and non-GAAP operating income increased by 13.1% to $251 million.

Dentsply Sirona reported a decrease in net sales and GAAP EPS, but an increase in non-GAAP operating income and non-GAAP EPS. Net sales were $895 million, a decrease of 7.0%. GAAP EPS was $0.25, a decrease of 34.2%, while non-GAAP EPS was $0.67, an increase of 17.5%.

Dentsply Sirona's Q2 2020 results were significantly impacted by the global response to COVID-19. The company reported a substantial decline in net sales and operating income compared to the prior year. In response to these challenges, Dentsply Sirona has implemented measures focused on employee safety, customer service, and financial stability, and is initiating additional restructuring actions to improve future performance.

Dentsply Sirona reported a decrease in net sales and a significant operating loss for Q1 2020, primarily due to the impact of the COVID-19 pandemic. While the beginning of the quarter showed solid revenue growth, the pandemic led to reduced demand and a goodwill impairment charge. The company is focusing on cost containment and strategic initiatives to navigate the disruption.

Dentsply Sirona reported Q4 2019 revenues of $1,112 million, up 4.9% compared to the prior year, with an 8.4% increase on an internal sales growth basis. The company's Q4 2019 EPS was $0.46, compared to $0.01 in Q4 2018, and non-GAAP EPS was $0.73, versus $0.58 in the prior year. Operating income increased 67% YoY to $137 million, while non-GAAP operating income grew 26% YoY to $222 million.